May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
In vitro Comparison of Antibiotic Resistance From 1996 to 2004 for Antibiotics Used for Conjunctivitis Therapy
Author Affiliations & Notes
  • B.R. Kowalski
    Ophthalmology, University of Pittsburgh, Pittsburgh, PA
  • R.P. Kowalski
    Ophthalmology, University of Pittsburgh, Pittsburgh, PA
  • E.G. Romanowski
    Ophthalmology, University of Pittsburgh, Pittsburgh, PA
  • F.S. Mah
    Ophthalmology, University of Pittsburgh, Pittsburgh, PA
  • Y.J. Gordon
    Ophthalmology, University of Pittsburgh, Pittsburgh, PA
  • Footnotes
    Commercial Relationships  B.R. Kowalski, None; R.P. Kowalski, Alcon Laboratories Inc., Ft. Worth, TX F; E.G. Romanowski, Alcon Laboratories Inc., Ft. Worth, TX F; F.S. Mah, Alcon Laboratories Inc., Ft. Worth, TX F; Y.J. Gordon, Alcon Laboratories Inc., Ft. Worth, TX F.
  • Footnotes
    Support  Alcon Laboratories Inc., Ft. Worth, TX
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2780. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B.R. Kowalski, R.P. Kowalski, E.G. Romanowski, F.S. Mah, Y.J. Gordon; In vitro Comparison of Antibiotic Resistance From 1996 to 2004 for Antibiotics Used for Conjunctivitis Therapy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2780.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the in vitro antibiotic resistant trends for common antibiotics used for the treatment of conjunctivitis. Methods: In a prospective study using stock isolates, disk diffusion susceptibility (NCCLS breakpoint interpretation) was determined for 3 groups of bacterial conjunctivitis isolates (Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae) to moxifloxacin (Mx), bacitracin (B), erythromycin (E), gentamicin (Gm), tobramycin (Tb), neomycin (Ne), ciprofloxacin (Cp), ofloxacin (Of), levofloxacin (Lv), trimethoprim (Tri), polymyxin B (PB), sulfa (S), and oxacillin (Ox–SA only). Antibiotic susceptibility was determined for two consecutive periods (1999 to 2004) and (1996 to 1999). Consecutive isolates were chosen from the most recent available for each period. The number of isolates for each bacterial group in the first period was 50 and 30 were used in the second period. Cumulative susceptibility for each period was compared and designated as increase, decrease, or no change in resistance. Results: Streptococcus pneumoniae – Resistance increased for 6 antibiotics (50%) (B, E, Gm, Tri, Pb, S), decreased for 4 (33%) (Cp, Of, Tb, and Lv), and there was no change for 2 (17%) (Mx, Ne). Staphylococcus aureus – Resistance increased for 4 (31%) (E, Pb, B, Ne), decreased for 7 (54%) (Mx, Tb, Gm, Tri, Of, Ox, Lv), and there was no change for 2 (15%) (S, Cp). Haemophilus influenzae – Resistance increased for 8 antibiotics (66%) (E, Of, Tri, Pb, Tb, S, Lv, Ne), decreased for 2 (17%) (B, Gm), and there was no change for 2 (17%) (Mx, Cp). Conclusions: Although there were trends of increased antibiotic resistance, some antibiotics noted a decrease in resistance and other antibiotics demonstrated no change in resistance. Recently–introduced topical moxifloxacin, lacking significant selection factors, demonstrated high susceptibility (100%) for St. pneumoniae and H. influenzae, and the highest susceptibility (82%) amongst the tested fluoroquinolones for S. aureus.

Keywords: conjunctivitis • antibiotics/antifungals/antiparasitics • bacterial disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×